A
Advait Nagle
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 25
Citations - 2796
Advait Nagle is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Plasmodium falciparum & Antimalarial Agent. The author has an hindex of 17, co-authored 25 publications receiving 2454 citations. Previous affiliations of Advait Nagle include Novartis.
Papers
More filters
Journal ArticleDOI
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
David Plouffe,Achim Brinker,Case W. McNamara,Kerstin Henson,Nobutaka Kato,Kelli Kuhen,Advait Nagle,Francisco Adrian,Jason T. Matzen,Paul A. Anderson,Tae-gyu Nam,Nathanael S. Gray,Arnab Chatterjee,Jeff Janes,S. Frank Yan,Richard E. Trager,Jeremy S. Caldwell,Peter G. Schultz,Yingyao Zhou,Elizabeth A. Winzeler +19 more
TL;DR: An efficient and robust high-throughput cell-based screen based on proliferation of Plasmodium falciparum in erythrocytes, which identified most known antimalarials and many novel chemical scaffolds, which likely act through both known and novel pathways.
Journal ArticleDOI
Targeting Plasmodium PI(4)K to eliminate malaria
Case W. McNamara,Marcus C. S. Lee,Chek Shik Lim,Siau Hoi Lim,Jason Roland,Oliver Simon,Bryan K. S. Yeung,Arnab K. Chatterjee,Susan McCormack,Micah J. Manary,Anne-Marie Zeeman,Koen J. Dechering,Tr Santha Kumar,Philipp P. Henrich,Kerstin Gagaring,Maureen Ibanez,Nobutaka Kato,Kelli Kuhen,Christoph Fischli,Advait Nagle,Matthias Rottmann,Matthias Rottmann,David Plouffe,Badry Bursulaya,Stephan Meister,Lucia E. Rameh,Joerg Trappe,Dorothea Haasen,Martijn Timmerman,Robert W. Sauerwein,Rossarin Suwanarusk,Bruce Russell,Bruce Russell,Laurent Rénia,François Nosten,David C. Tully,Clemens H. M. Kocken,Richard Glynne,Christophe Bodenreider,David A. Fidock,Thierry T. Diagana,Elizabeth A. Winzeler,Elizabeth A. Winzeler +42 more
TL;DR: It is shown that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate.
Journal ArticleDOI
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Stephan Meister,David Plouffe,Kelli Kuhen,Ghislain M. C. Bonamy,Tao Wu,S. Whitney Barnes,Selina Bopp,Rachel Borboa,A. Taylor Bright,A. Taylor Bright,Jianwei Che,Steve Cohen,Neekesh V. Dharia,Kerstin Gagaring,Montip Gettayacamin,Perry Gordon,Todd Groessl,Nobutaka Kato,Marcus C. S. Lee,Case W. McNamara,David A. Fidock,Advait Nagle,Tae-gyu Nam,Wendy Richmond,Jason Roland,Matthias Rottmann,Matthias Rottmann,Bin Zhou,Patrick Froissard,Patrick Froissard,Richard Glynne,Dominique Mazier,Dominique Mazier,Jetsumon Sattabongkot,Peter G. Schultz,Tove Tuntland,John R. Walker,Yingyao Zhou,Arnab K. Chatterjee,Thierry T. Diagana,Elizabeth A. Winzeler,Elizabeth A. Winzeler +41 more
TL;DR: An imidazolopiperazine scaffold series was identified that was highly enriched among compounds active against Plasmodium liver stages and shows potent in vivo blood-stage therapeutic activity.
Journal ArticleDOI
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare,Advait Nagle,Agnes Biggart,Yin H. Lai,Fang Liang,Lauren C. Davis,S. Whitney Barnes,Casey J. N. Mathison,Elmarie Myburgh,Elmarie Myburgh,Mu-Yun Gao,J. Robert Gillespie,Xianzhong Liu,Jocelyn Tan,Monique Stinson,Ianne C. Rivera,Jaime Ballard,Vince Yeh,Todd Groessl,Glenn C. Federe,Hazel X. Y. Koh,John D. Venable,Badry Bursulaya,Michael Shapiro,Pranab Mishra,Glen Spraggon,Ansgar Brock,Jeremy C. Mottram,Jeremy C. Mottram,Frederick S. Buckner,Srinivasa P. S. Rao,Ben G. Wen,John R. Walker,Tove Tuntland,Valentina Molteni,Richard Glynne,Frantisek Supek +36 more
TL;DR: A selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection, underscores the possibility of developing a single class of drugs for these neglected diseases.
Journal ArticleDOI
Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.
Advait Nagle,Shilpi Khare,Arun Kumar,Frantisek Supek,Andriy Buchynskyy,Casey J. N. Mathison,Naveen Kumar Chennamaneni,Nagendar Pendem,Frederick S. Buckner,Michael H. Gelb,Valentina Molteni +10 more
TL;DR: The disease history and parasite biology is described followed by a summary of the currently available treatments and, finally, review reports of novel small molecules with antileishmanial activity.